author-photo

Martin Markowitz

Rockefeller University

43

Papers

5181

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China

2019 Aids and Behavior
Show All
- Source
- Cite
- Save
Citations (21)
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

2018 Aids and Behavior
Show All
- Source
- Cite
- Save
Citations (19)
Challenges in Recruiting People Who Use Drugs for HIV-Related Biomedical Research: Perspectives from the Field

2016 Aids Patient Care and Stds
Show All
- Source
- Cite
- Save
Citations (5)
Impact of HLA-B*13-associated polymorphisms in HIV-1 Gag and Pol on viral replication capacity

2014
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

2013 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (105)
Next-Generation Integrase Inhibitors Where to After Raltegravir?

2013 Drugs
- Sharon L. Karmon
- Martin Markowitz
Show All
- Source
- Cite
- Save
Citations (43)
Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

2012 Journal of Virology
Show All
- Source
- Cite
- Save
Citations (32)
Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection

2011 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (147)
Molecular and functional consequences of immune-mediated evolution in HIV-1 Nef during the North American epidemic.

2011
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

2010 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (43)